A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan

Trial Profile

A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Molidustat (Primary) ; Epoetin alfa; Epoetin alfa; Epoetin beta; Epoetin beta
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms DIALOGUE4
  • Sponsors Bayer
  • Most Recent Events

    • 11 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 15 Oct 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Oct 2015 as reported by ClinicalTrials.gov.
    • 15 Oct 2015 Planned End Date changed from 1 Mar 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top